Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.790
+0.060 (3.47%)
At close: Sep 26, 2025, 4:00 PM EDT
1.840
+0.050 (2.79%)
After-hours: Sep 26, 2025, 7:05 PM EDT
Gain Therapeutics Employees
As of December 31, 2024, Gain Therapeutics had 25 total employees, including 23 full-time and 2 part-time employees. The number of employees decreased by 7 or -21.88% compared to the previous year.
Employees
25
Change (1Y)
-7
Growth (1Y)
-21.88%
Revenue / Employee
n/a
Profits / Employee
-$743,723
Market Cap
64.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | -7 | -21.88% |
| Dec 31, 2023 | 32 | 1 | 3.23% |
| Dec 31, 2022 | 31 | 2 | 6.90% |
| Dec 31, 2021 | 29 | 15 | 107.14% |
| Dec 31, 2020 | 14 | 10 | 250.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GANX News
- 3 days ago - Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 - GlobeNewsWire
- 8 days ago - Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease - GlobeNewsWire
- 22 days ago - Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation - GlobeNewsWire